Table 2.
Pulmonary characteristics of the patient cohort at the time of allo-HCT.
| Pulmonary clinical characteristics | |||
|---|---|---|---|
| Conditioning protocol | FBM | FTM | p value |
| Pulmonary disease prior allo-HCT, n (%) | 44 (33.1) | 49 (46.7) | 0.04 |
| Bact. pneumonia | 16 (11.8) | 15 (14.3) | |
| Fungal pneumonia | 8 (5.9) | 8 (7.6) | |
| Atypical pneumonia | 5 (3.7) | 4 (3.8) | |
| PjP pneumonia | 0 | 2 (1.9) | |
| Influenza A pneumonia | 0 | 2 (1.9) | |
| Asthma/COPD | 1 (0.7) | 13 (12.3) | |
| Pulmonary embolism | 5 (3.7) | 6 (5.7) | |
| Pleural effusions | 4 (2.9) | 3 (2.8) | |
| Previous tuberculosis | 4 (2.9) | 0 | |
| Bronchitis | 1 (0.7) | 2 (1.9) | |
| Sleep apnea | 1 (0.7) | 2 (1.9) | |
| Others | 4 (2.9) | 5 (4.8) | |
| Current and previous smokers, n (%) | 45 (33.1) | 49 (46.7) | 0.04 |
| Pulmonary lung function test before allo-HCT, n (%)a | 120 (89.5%) | 96 (91.4%) | |
| FEV1 (% of predicted) | 97 (53–145) | 95 (23–138) | 0.02 |
| FEV1/VCmax ratio | 0.75 (0.49–1.03) | 0.74 (0.18–0.99) | 0.05 |
| FEV1/FVC ratio | 0.79 (0.55–0.99) | 0.77 (0.35–1.00) | 0.02 |
| FVC (% of predicted) | 103 (47–159) | 99 (43–147) | 0.02 |
| MEF50 (% of predicted) | 68.3 (19–150) | 65.5 (2.5–137) | 0.03 |
| MEF25 (% of predicted) | 44.8 (9–137) | 45.1 (9–103) | 0.38 |
| DLCOcSB (% of predicted) | 76.9 (36–127) | 68.0 (21–106) | 0.001 |
| RV (% of predicted) | 108.5 (44–349) | 110 (59–370) | 0.27 |
| RV/TLC ratio | 0.39 (0.10–1.40) | 0.40 (0.22–1.35) | 0.15 |
| TLC (% of predicted) | 99.9 (60–159) | 100.0 (71.5–159) | 0.53 |
| Arterial CO2, mm Hg | 35 (26–43) | 35 (24–44) | 0.37 |
| Arterial O2, mmHg | 77.7 (62–106) | 79.0 (59–102) | 0.20 |
Statistical analysis of categorical variables was performed by Pearson’s chi-square and Fisher’s exact test; continuous variables by Student’s T-test assuming a normal distribution.
allo-HCT allogeneic hematopoietic cell transplantation, RV residual volume, TLC total lung capacity, VCmax maximal vital capacity, FEV1 forced expiratory volume in 1 s, FEV1/FVC FEV1/forced vital capacity (FVC), MEF50 mid-expiratory flow 50%, MEF25 mid-expiratory flow 25%, aCO2 arterial carbon dioxide, aO2 arterial oxygen, DLCOcSB diffusion capacity of carbon monoxide adjusted for hemoglobin level, FBM fludarabine, BCNU/carmustine, melphalan, FTM fludarabine, thiotepa, melphalan.
aData are presented as median(range).